Immunogenicity to cerliponase alfa, an enzyme replacement therapy for patients with CLN2 disease: results from a phase 1/2 study

被引：0
|
作者：
Cherukuri, Anu [1 ]
Cahan, Heather [1 ]
Van Tuyl, Andrea [1 ]
de Hart, Greg [1 ]
Slasor, Peter [1 ]
Bray, Laurie [1 ]
Henshaw, Josh [1 ]
Ajayi, Temitayo [1 ]
Jacoby, Dave [1 ]
O'Neill, Charles [1 ]
Schweighardt, Becky [1 ]
机构：
[1] BioMarin Pharmaceut Inc, Novato, CA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期
关键词：
D O I：
10.1016/j.ymgme.2016.11.064
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
55
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [1] Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study
    Cherukuri, Anu
    Cahan, Heather
    de Hart, Greg
    Van Tuyl, Andrea
    Slasor, Peter
    Bray, Laurie
    Henshaw, Joshua
    Ajayi, Temitayo
    Jacoby, Dave
    O'Neill, Charles A.
    Schweighardt, Becky
    CLINICAL IMMUNOLOGY, 2018, 197 : 68 - 76
  • [2] Cerliponase alfa for CLN2 disease, a promising therapy
    Aylward, Shawn C.
    Pindrik, Jonathan
    Abreu, Nicolas J.
    Cherny, W. Bruce
    O'Neal, Matthew
    de Los Reyes, Emily
    EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (11): : 445 - 454
  • [3] Study of Intraventricular Cerliponase Alfa for CLN2 Disease
    Schulz, Angela
    Ajayi, Temitayo
    Specchio, Nicola
    de Los Reyes, Emily
    Gissen, Paul
    Ballon, Douglas
    Dyke, Jonathan P.
    Cahan, Heather
    Slasor, Peter
    Jacoby, David
    Kohlschutter, Alfried
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (20): : 1898 - 1907
  • [4] Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
    Kim, Aryun
    Grover, Anita
    Hammon, Kevin
    de Hart, Greg
    Slasor, Peter
    Cherukuri, Anu
    Ajayi, Temitayo
    Jacoby, David
    Schulz, Angela
    Specchio, Nicola
    de Los Reyes, Emily
    Gissen, Paul
    Henshaw, Joshua W.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (02): : 635 - 644
  • [5] Long-Term Safety and Efficacy of Intracerebroventricular Enzyme Replacement Therapy with Cerliponase Alfa in Children with CLN2 Disease: 2 Year Results from an Ongoing Multicenter Extension Study
    Jacoby, David
    Schulz, Angela
    Specchio, Nicola
    Reyes, Emily de Los
    Gissen, Paul
    Cahan, Heather
    Ajayi, Temitayo
    ANNALS OF NEUROLOGY, 2017, 82 : S165 - S165
  • [6] Progressive retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in classic late-infantile CLN2 disease
    Atiskova, Yevgeniya
    Schwering, Christoph
    Wildner, Jan
    Spartalis, Christoph
    Schuttauf, Frank
    Bartsch, Udo
    Wibbeler, Eva
    Nickel, Miriam
    Spitzer, Martin
    Schulz, Angela
    Dulz, Simon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [7] Long-term Safety and Efficacy of Intracerebroventricular Enzyme Replacement Therapy with Cerliponase Alfa in Children with CLN2 Disease: Two Year Results from an Ongoing Multicenter Extension Study
    de Los Reyes, E.
    Schulz, A.
    Specchio, N.
    Gissen, P.
    Lehwald, L.
    Cahan, H.
    Slasor, P.
    Ajayi, T.
    Jacoby, D.
    ANNALS OF NEUROLOGY, 2018, 84 : S351 - S351
  • [8] Long-term safety and efficacy of intracerebroventricular enzyme replacement therapy with cerliponase alfa in children with CLN2 disease: interim results from an ongoing multicenter, multinational extension study
    Schulz, Angela
    Specchio, Nicola
    Gissen, Paul
    de los Reyes, Emily
    Cahan, Heather
    Slasor, Peter
    Ajayi, Temitayo
    Jacoby, David
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S120 - S120
  • [9] Psychometric Validation of the CLN2 Quality of Life Questionnaire in Participants with CLN2 Disease Treated with Cerliponase Alfa
    Due, Christina
    Quinn, Jennifer
    Gissen, Paul
    Schulz, Angela
    Specchio, Nicola
    de los Reyes, Emily
    Butt, Thomas
    HEALTHCARE, 2024, 12 (22)
  • [10] Long-term safety and efficacy of intracerebroventricular enzyme replacement therapy with cerliponase alfa in children with CLN2 disease: Two year results from an ongoing multicenter extension study
    Schulz, Angela
    Specchio, Nicola
    Gissen, Paul
    de los Reyesd, Emily
    Cahan, Heather
    Slasor, Peter
    Ajayi, Temitayo
    Jacoby, David
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S126 - S127
12345